Compare ADMA Biologics Inc (ADMA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Medpace Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.35 (market cap $2.19B), while Medpace Holdings Inc trades at $582 (market cap $16.66B). The key difference: Medpace Holdings Inc is far larger — about 7.6× ADMA Biologics Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | MEDP | |
|---|---|---|
Market Cap | $2.19B | $16.66B |
Sector | Health | Technology |
52-Week High | $20.38 | $620.59 |
52-Week Low | $7.60 | $393.42 |
Enterprise Value | $2.26B | $16.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA Biologics trades at $9.78, down 1.26% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. Technical indicators suggest a bullish trend with RSI levels indicating potential overbought conditions. The company faces multiple securities lawsuits while maintaining strong analyst support with 89% buy ratings.
The outlook remains cautiously optimistic given strong fundamentals and analyst consensus, though legal challenges and recent earnings misses present near-term headwinds. Key opportunities include ASCENIV product growth and improved cash flow projections for 2026, while risks center on litigation outcomes and competitive pressures in the IG market.
MEDP trades at $596.98, down 1.41% today but maintains a bullish technical outlook with strong moving average support. The company demonstrates robust fundamentals with 17.2% YoY revenue growth in Q2 2026 and consistent earnings beats, though valuation metrics remain elevated with a P/E of 35.08. Recent news highlights record Q2 bookings and raised 2026 guidance, while technical indicators show the stock trading near pivot point resistance at $598.
MEDP presents a growth opportunity with strong operational performance and positive analyst sentiment, though premium valuation and potential legal scrutiny pose risks. The stock's technical strength and fundamental momentum support further upside toward the $692 price target, but investors should monitor the ongoing legal investigation and valuation compression risks in a volatile market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
